期刊文献+

非小细胞肺癌患者血清肝癌衍生生长因子、血管内皮生长因子的水平及意义 被引量:1

Expressions and significances of serum hepatic cancer-derived growth factor and vascular endothelial growth factor in patients with non-small cell lung cancer
原文传递
导出
摘要 目的探讨肝癌衍生生长因子(HDGF)、血管内皮生长因子(VEGF)在非小细胞肺癌(NSCLC)患者血清中的表达及意义。方法选择非小细胞肺癌患者30例为肺癌组,良性肺部疾病患者30例为良性肺病组,健康人30例为对照组。比较各组血清HDGF、VEGF水平,分析肺癌组患者血清HDGF、VEGF水平的相关因素,对肺癌组患者血清HDGF、VEGF水平进行相关性分析。结果良性肺病组血清HDGF水平高于对照组(P<0.01),VEGF水平低于对照组(P<0.01)。肺癌组血清HDGF、VEGF水平高于对照组(P<0.01);HDGF水平低于良性肺病组(P<0.01),VEGF水平高于良性肺病组(P<0.01)。肺癌组血清HDGF、VEGF水平与性别、年龄无统计学相关,与吸烟、病理类型、分化程度、病理分期、淋巴结转移密切相关。肺癌组患者血清HDGF、VEGF水平呈正相关(r=0.33,P<0.01)。结论血清HDGF水平与肺癌分期密切相关,血清VEGF水平、淋巴结状态与肺癌分期密切相关,二者对NSCLC患者病程的判定有一定帮助。 Objective To explore the expressions and significances of serum hepatic cancer-derived growth factor (HDGF)and vascular endothelial growth factor (VEGF)in patients with non-small cell lung cancer (NSCLC). Methods A total of 30 patients with NSCLC served as NSCLC group while other 30 patients with benign lung disease as benign lung disease group,and 30 healthy people as control group.Serum HDGF and VEGF levels were compared among the three groups and analyzed in NSCLC group for their relevant factors and relationship.Results Benign lung disease group was evidently higher in serum HDGF level and lower in VEGF level than control group (P〈0.01 ), while NSCLC group was obviously higher than control group in both HDGF and VEGF levels (P〈0.01 ).However, NSCLC group was markedly lower in HDGF level but higher in VEGF level than benign lung disease group (P〈0.01).Serum HDGF and VEGF levels had no significant relationship with ages and genders in NSCLC group,but they had apparent association with smoking history,adeno-carcinoma,non- and low- differentiation,pathological stage and lymph node metastasis.Serum HDGF and VEGF levels were positively correlated(r=0.33,P〈0.01).Conclusion Serum HDGF level has close association with clinical stages,and serum VEGF level is closely correlated with conditionsof lymph nodes and clinical stages of lung cancers,so they are helpful in the diagnosis of NSCLC.
出处 《山东大学学报(医学版)》 CAS 北大核心 2014年第9期63-66,共4页 Journal of Shandong University:Health Sciences
关键词 肝癌衍生生长因子 血管内皮生长因子 非小细胞肺 血清 Hepatic cancer-derived growth factor Vascular endothelial growth factor Non-small cell lung cancer Serum
  • 相关文献

参考文献15

  • 1洪群英,张勇,白春学.肺癌筛查和早期诊断的现状[J].国际呼吸杂志,2013,33(24):1888-1891. 被引量:6
  • 2Zhao J, Ma M Z, Ren H, et al. Anti-HDGF targets canc- er and cancer stromal stem cells resistant to chemotherapy [J]. Clin Cancer Res, 2013, 19(13) :3567-3576.
  • 3周世杰,许绍发,张海青,刘志东.肝癌衍生生长因子在Ⅰ期非小细胞肺癌中的表达及其临床意义[J].中华肿瘤杂志,2007,29(12):927-930. 被引量:4
  • 4Nakamura H, Izumoto Y, Kambe H, et al. Molecular cloning of complementary DNA for a novel human hepa- toma-derived growth factor. Its homology with high mob- ility group-1 protein[J]. J Biol Chem, 1994, 269(40) : 25143-25149.
  • 5Ke Y, Zhao W, Xiong J, et al. Downregulation of miR- 16 promotes growth and motility by targeting HDGF in non-small cell lung cancer cells [ J]. FEBS Lett, 2013, 587(18) :3153-3157.
  • 6Iwasaki T, Nakagawa K, Nakamura H, et al. Hepatoma- derived growth factor as a prognostic marker in complete- ly resected non-small-cell lung cancer [ J ]. Oncol Rep, 2005, 13 (6) : 1075-1080.
  • 7Kim J W, Koh Y, Kim D W, et al. Clinical implications of VEGF, TGF-β1, and IL-1β in patients with advanced non-small cell lung cancer[ J]. Cancer Res Treat, 2013,45 (4) :325-333.
  • 8Zhao Y, Yu D, Wu H, et al. Anticancer activity of SA- HA, a potent histone deacetylase inhibitor, in NCI-H460 human large-cell lung carcinoma cells in vitro and in vivo [J]. Int J Oncol, 2014, 44(2) :451-458.
  • 9Smith N R, Baker D, Farren M, et al. Tumor stromal ar- chitecture can define the intrinsic tumor response to VEGF-targeted therapy [ J ]. Clin Cancer Res, 2013, 19 (24) :6943-6956.
  • 10李白翎,金磊,钟铿,韩林.非小细胞肺癌组织Bmi-1和VEGF表达及其临床意义的研究[J].中华肿瘤防治杂志,2012,19(21):1610-1613. 被引量:5

二级参考文献88

  • 1李高峰,段林灿,陈明清.血管内皮生长因子与非小细胞肺癌关系的研究进展[J].昆明医学院学报,2004,25(4):94-98. 被引量:2
  • 2王志刚,孙杰,黄一东,程可洛,梁克.血管内皮生长因子表达与非小细胞肺癌侵袭、淋巴结转移的关系[J].肿瘤研究与临床,2006,18(11):746-747. 被引量:9
  • 3Nakamura H, Izumoto Y, Kambe H, et al. Molecular cloning of complementary DNA for a novel human hepatoma-derived growth factor. Its homology with high mobility group-1 protein. J Biol Chem, 1994, 269:25143-25149.
  • 4Ben H, Tang X, Lee JJ, et al. Expression of hepatoma-derived growth factor is a strong prognostic predictor for patients with early-stage nonsmall-cell lung cancer. J Clin Oneol, 2004, 22:3230-3237.
  • 5Yano T, Tanikawa S, Fujie T, et al. Vascular endothelial growth factor expression and neovascularisation in non-small cell lung cancer. Eur J Cancer, 2000, 36:601-609.
  • 6Okuda Y, Nakamura H, Yoshida K, et al. Hepatoma-derived growth factor induces tumorigenesis in vivo through both direct angiogenic activity and induction of vascular endothelial growth factor. Cancer Sci, 2003, 94 : 1034-1041.
  • 7Oliver JA, A1-Awqati Q. An endothelial growth factor involved in rat renal development. J Clin Invest, 1998, 102: 1208-1219.
  • 8Moil M, Morishita H, Nakamura H, et al. Hepatoma-defived growth factor is involved in lung remodeling by stimulating epithelial growth. Am J Respir Cell Mol Biol, 2004, 30:459-469.
  • 9Machuy N, Thiede B, Rajalingam K, et al. A global approach combining proteome analysis and phenotypic screening with RNA interference fields novel apoptosis regulators. Mol Cell Proteomies, 2005, 4:44-55.
  • 10Enomoto H, Yoshida K, Kishima Y, et al. Participation of hepatoma-derived growth factor in the regulation of fetal hepatocyte proliferation. J Gastroenterol, 2002, 37 Suppl 14:158-161.

共引文献26

同被引文献16

  • 1Adachi M,Mizuno M,Mitsui H,et al. The prognostic impact of pulmonary metastasectomy in recurrent gynecologic cancers: a retrospective single-institution study[J]. Nagoya J Med Sci, 2015,77 (3):363-372.
  • 2Hanagiri T,Shinohara S, Takenaka M, et al. Clinical character- istics of resected T3 non-small cell lung cancer characterized by parietal pleural invasion or chest wall invasion[J]. Indian J Surg, 2014,76(5) : 354-358.
  • 3Chaudhry A,Grechushkin V, Hoshmand M,et al. Characteristic CT findings after percutaneous cryoablation treatment of malig- nant lung nodules [ J ]. Medicine ( Baltimore), 2015, 94 ( 42 ) : e1672.
  • 4Zhou T,Chen Y,Li L,et al. Non-extended cryoablation could be a new strategy in lung cancer management : An experiment on green fluorescent protein-labeled Lewis lung cancer bearing mice[J]. Cryobiology,2015,71(1) :40-46.
  • 5de Baere T,Tselikas L,Woodrum D,et al. Evaluating cryoabla- tion of metastatic lung tumors in patients-safety and efficacy: the ECLIPSE trial-interim analysis at 1 year[J]. J Thorac On- col, 2015,10 (10) : 1468-1474.
  • 6Gao L,Li Q,Jiang M, et al. Combined therapy of percutaneous cryoablation and traditional Chinese medicine can be a promis- ing strategy for elderly or advanced lung cancer patients based on a retrospective clinical study[J]. Cryobiology, 2014,69 ( 1 ):174-177.
  • 7Niu L,Chen J,Yao F,et al. Percutaneous cryoablation for stage lung cancer:a retrospective analysis[J]. Cryobiology,2013, 67(2):151 -155.
  • 8Wang B, He YJ, Tian YX, et al. Clinical utility of haptoglobin in combination with CEA, NSE and CYFRA21-1 for diagnosis of lung cancer[J]. Asian Pac J Cancer Prev,2014,15(22):9611- 9614.
  • 9Yu Z, Chen XZ, Cui LH, et al. Prediction of lung cancer based on serum biomarkers by gene expression programming methods [J]. AsianPacJ Cancer Prev,2014,15(21) :9367-9373.
  • 10Kumagai T, Tomita Y, Inoue T, et al. Pleural sarcoidosis diag- nosed on the basis of an increased CD4/CD8 lymphocyte ratio in pleural effusion fluid:a case report[J]. J Med Case Rep,2015, 9:170.

二级引证文献3

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部